The Trump administration is speeding up the review of some psychedelic drugs, including ibogaine, which have been classified as Schedule I. The Food and Drug Administration is issuing vouchers that could reduce its review time from months to weeks. Dr. Jean Loftus, a Northern Kentucky plastic surgeon, believes this move breaks down barriers that would otherwise be looking at. She also highlighted the potential life-changing potential for those suffering from severe mental illness and depression. The executive order also directs at least $50 million to states that establish programs for advancing psychedelics.